<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559114</url>
  </required_header>
  <id_info>
    <org_study_id>0785</org_study_id>
    <nct_id>NCT03559114</nct_id>
  </id_info>
  <brief_title>PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)</brief_title>
  <acronym>PROTEST</acronym>
  <official_title>PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study, phase III, multi-centre, double blind, randomized controlled trial of&#xD;
      patients with traumatic brain injury (TBI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe brain injury are at risk for developing blood clots in their legs, which&#xD;
      can travel to the lungs. This potentially serious complication is known as venous&#xD;
      thromboembolism (VTE). Anticoagulants are commonly used to prevent VTE in hospital patients.&#xD;
      However, in patients with major head injury, anticoagulant prevention is commonly delayed for&#xD;
      the fear that it can potentially lead to further bleeding in the brain. Another method that&#xD;
      aims to prevent blood clots involves the use of sequential compression device (SCD) that&#xD;
      compress the legs and increase the flow of blood in the leg veins.&#xD;
&#xD;
      This study will compare results from patients who receive the SCDs only to those who receive&#xD;
      both SCD and anticoagulants. The outcome of this study will provide information about how&#xD;
      best to prevent blood clots while not increase brain bleeding after head injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically important VTE</measure>
    <time_frame>8 days</time_frame>
    <description>Composite outcome of clinically-important VTE within 7±1 days after randomization defined as any of:&#xD;
Symptomatic, objectively-confirmed pulmonary embolism (PE), or&#xD;
Symptomatic, objectively-confirmed, proximal leg deep vein thrombosis (DVT), or&#xD;
Proximal (above knee) leg DVT on compression ultrasonography on Day 7±1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically-important ICB (Intracranial bleeding) progression</measure>
    <time_frame>7 days</time_frame>
    <description>Clinically-important ICB progression within 7±1 days after randomization , as defined by having (1) any increase in volume of blood in the brain on any CT scan within 7±1 days relative to initial CT scan on Day 0* AND (2) clinical worsening within 24 hours of this CT scan, defined by one or more of the following:&#xD;
Surgical intervention related to increased ICB after Day 0 (craniotomy/craniectomy, ICP monitor, external ventricular drain)&#xD;
Decrease of GCS (Glasgow Coma Scale) by at least 2 points not related to sedation&#xD;
Increase in ICP &gt;5 mmHg on 2 occasions at least 6 hours apart despite medical therapy (if ICP monitor is in place)&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objectively confirmed new or progressing ICB on radiology,</measure>
    <time_frame>8 days</time_frame>
    <description>Assessed by comparing the initial brain CT (Day 0) to that performed within 8±1 days following randomization (or most recent prior to death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>180-day Mortality</measure>
    <time_frame>180 days</time_frame>
    <description>Mortality at 180 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>7-day Mortality</measure>
    <time_frame>7 days</time_frame>
    <description>Mortality at 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Mortality at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed VTE after day 7</measure>
    <time_frame>30 days</time_frame>
    <description>Any clinically important VTE occurring between Day 8 to Day 30 detected by treating clinicians</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcome at day 30 as measured by Glasgow Outcome Scale Extended</measure>
    <time_frame>30 days</time_frame>
    <description>Glasgow Outcome Scale Extended (GOSE) at Day 30±5 by phone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological outcome at day 180 as measured by Glasgow Outcome Scale Extended</measure>
    <time_frame>180 days</time_frame>
    <description>Glasgow Outcome Scale Extended (GOSE) at Day 180±14 by phone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome at 30 days as measured by the EuroQol5D</measure>
    <time_frame>30 days</time_frame>
    <description>EQ-5D (EuroQol 5D) at Day 30±5 by phone interview.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life outcome at 180 days as measured by the EuroQol5D</measure>
    <time_frame>180 days</time_frame>
    <description>EQ-5D (EuroQol 5D) at Day 180±14 by phone interview.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Anticoagulant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Dalteparin in prophylactic doses administered daily if screening criteria are satisfied.</description>
    <arm_group_label>Anticoagulant</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline in prophylactic doses administered daily if screening criteria are satisfied.</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        The pragmatic nature of this study seeks to include all consecutive patients presenting&#xD;
        with significant TBI, regardless of whether ICB is evident at presentation. Inclusion&#xD;
        criteria are the following:&#xD;
&#xD;
        i) Patients with severe and moderate acute TBI defined as:&#xD;
&#xD;
          1. GCS of ≤8 or&#xD;
&#xD;
          2. GCS of 9-12 (moderate) with any intracranial hemorrhage seen on CT scan (patients with&#xD;
             only subarachnoid hemorrhage are excluded)&#xD;
&#xD;
        ii) Upon randomization patient can receive the first dose of study drug in the first 3&#xD;
        calendar days of the time of injury&#xD;
&#xD;
        ii) ≥ 18 years of age&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        All participants meeting any of the following exclusion criteria at baseline will be&#xD;
        excluded from participation in this study:&#xD;
&#xD;
        i) Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl&#xD;
        alcohol or to other low molecular weight heparins and/or heparins or pork products&#xD;
&#xD;
        ii) Known history of confirmed or suspected immunologically-mediated heparin-induced&#xD;
        thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known&#xD;
        history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN&#xD;
        (Dalteparin) is positive&#xD;
&#xD;
        iii) Known septic endocarditis&#xD;
&#xD;
        iv) Uncontrollable active bleeding&#xD;
&#xD;
        v) Known major blood clotting disorders&#xD;
&#xD;
        vi) Known acute gastroduodenal ulcer (with active bleeding)&#xD;
&#xD;
        vii) Severe uncontrolled hypertension (i.e. BP&gt;210 despite medications)&#xD;
&#xD;
        viii) Known diabetic or hemorrhagic retinopathy&#xD;
&#xD;
        ix) Anticipated to be unable to receive SCD on at least one lower extremity due to nature&#xD;
        of injuries for duration of intervention period&#xD;
&#xD;
        x) Presence of another confounding factor that can adequately explain the poor GCS at time&#xD;
        of presentation (e.g. drug toxicity, seizure)&#xD;
&#xD;
        xi) Known presence of irreversible coagulopathies&#xD;
&#xD;
        xii) Known Pregnancy&#xD;
&#xD;
        xiii) Participants extremely low weight (&lt;45 kg), or extremely high weight (&gt;120kg)&#xD;
&#xD;
        xiv) Not expected to survive more than 48 hours from admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Pirouzmand, MD, MSc, FRCSC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damon Scales, MD, PhD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farhad Pirouzmand, MD, MSc, FRCSC</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>5263</phone_ext>
    <email>farhad.pirouzmand@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catarina Downey, MSc, CCRP</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>87546</phone_ext>
    <email>protest@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaleen Maharaj</last_name>
      <email>Shaleen.Maharaj@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Andreas Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrica Thompson</last_name>
      <email>patrica.thompson@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tayne Hewer</last_name>
      <email>tayne.hewer@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Kutsogiannis, MD, MHS, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrica Thompson</last_name>
      <email>patrica.thompson@albertahealthservices.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tayne Hewer</last_name>
      <email>tayne.hewer@albertahealthservices.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jim Kutsogiannis, MD, MHS, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Grey</last_name>
      <email>Rebecca.Grey@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Donald Griesdale, MD, MPH, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura-Lee Magennis</last_name>
      <email>Laura.Magennis@nshealth.ca</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Julien</last_name>
      <email>lisa.julien@nshealth.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Sean Christie, MD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurel Murphy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Martyniuk</last_name>
      <email>martynia@mcmaster.ca</email>
    </contact>
    <investigator>
      <last_name>Sunjay Sharma, MD, MSc, FRCSC, FACS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Engels, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7N 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Boyd</last_name>
      <email>Tracy.Boyd@kingstonhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Gordon Boyd, MD, PhD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>KIH 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Porteous</last_name>
      <email>rporteous@ohri.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sydney Mietzitis</last_name>
      <email>smiezitis@ohri.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Shane English, MD, MSc, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Science Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Farhad Pirouzmand, MD, MSc, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damon Scales, MD, PhD, FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Junk</last_name>
      <email>emily.junk@usask.ca</email>
    </contact>
    <investigator>
      <last_name>Gary Hunter, MD, FRCPC, CSCN (EEG)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>June 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2018</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sequential Compression Device</keyword>
  <keyword>Anticoagulant Thromboprophylaxis</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Sub Cutaneous</keyword>
  <keyword>VTE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

